Actively Recruiting

Phase 3
Age: 10Years - 17Years
All Genders
ID03588975

A Prospective, Open-label, Randomized, Controlled Phase 3 Study of MACI in Patients 10 to 17 Years With Symptomatic Knee Chondral or Osteochondral Defects

Led by Vericel Corporation · Updated on 2024-12-02

45

Participants Needed

12

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and safety of MACI compared to arthroscopic microfracture for treating young patients aged 10 to 17 years who have symptomatic cartilage or osteochondral defects in the knee. This phase 3 clinical trial seeks to understand which treatment better improves pain and function related to these knee defects. This study randomly assigns a total of 45 patients into two groups: 30 will receive a single treatment with MACI, which involves autologous cultured chondrocytes on a porcine collagen membrane, and 15 will receive arthroscopic microfracture treatment during a screening arthroscopy. Patients assigned to MACI return within 12 weeks for the cell implantation surgery and follow a recommended rehabilitation program. The trial lasts for two years after treatment to monitor outcomes. Participants undergo a screening arthroscopy to confirm eligibility and have a cartilage biopsy taken before treatment. Researchers will monitor cartilage lesion size, compliance with rehabilitation, and measure improvements in knee pain and function using KOOS-Child scores over 104 weeks. Safety and efficacy are tracked carefully throughout the study period.

CONDITIONS

Brief Title

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Who Can Participate

Age: 10Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 10 to 17 years
  • Symptomatic cartilage or osteochondral defects in the knee
  • One or more ICRS Grade III or IV defects on femoral condyles and/or trochlea suitable for MACI or microfracture
  • Defect size at least 1.5 cm2 on femoral condyles and/or trochlea; includes OCD lesions with bone depth up to 6 mm without need for bone graft
  • Stable target knee with intact or at least 50% functional meniscus
  • Ligaments stable and intact; prior ligament repair or reconstruction allowed before screening arthroscopy
Not Eligible

You will not qualify if you...

  • Surgery on target knee within 6 months before screening (excluding diagnostic arthroscopy)
  • ICRS Grade III or IV defects on patella or tibia or bipolar lesions
  • Inflammatory or other joint-affecting diseases (e.g., rheumatoid arthritis, metabolic bone disease, psoriasis, chondrocalcinosis)
  • History of septic arthritis in the target knee
  • Known allergy to gentamicin, aminoglycosides, or porcine/bovine products
  • Females who are pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) including screening arthroscopy

Treatment

Duration - Up to 12 weeks from screening to MACI implantation or microfracture procedure

Participants receive a one-time surgical treatment with either MACI implant or microfracture procedure.

1 surgical visit for treatment; MACI participants return for implantation within 12 weeks of screening arthroscopy

Post-operative Follow-up

Duration - 2 years (104 weeks)

Participants follow a recommended rehabilitation program and are monitored for recovery and treatment outcomes.

Regular follow-up visits over 2 years to assess recovery and outcomes

Trial Site Locations

Total: 12 locations

1

Stanford University

Palo Alto, California, United States, 94304

Actively Recruiting

2

Shriner's Hospital for Children Northern California

Sacramento, California, United States, 95817

Actively Recruiting

3

University of California Davis Health

Sacramento, California, United States, 95817

Actively Recruiting

4

Ochsner Sports Medicine Institute

New Orleans, Louisiana, United States, 70121

Actively Recruiting

5

Johns Hopkins Outpatient Center

Baltimore, Maryland, United States, 21224

Actively Recruiting

6

University of Michigan

Ann Arbor, Michigan, United States, 48106

Actively Recruiting

7

Akron Children's Hospital

Akron, Ohio, United States, 44308

Actively Recruiting

8

The Ohio State University Jameson Crane Sports Medicine Institute

Columbus, Ohio, United States, 43202

Actively Recruiting

9

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

10

Penn Sports Medicine Center

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

11

Texas Children's Hospital

Houston, Texas, United States, 77094

Withdrawn

12

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53201

Actively Recruiting

Loading map...

Research Team

M

Mikhail Chkolnik, MD

K

Kristin M Tripp, BS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Prospective, Open-label, Randomized, Active-controlled Pha...

Chondral Defect

Actively Recruiting

4 locations

Autologous Matrix-Induced Chondrogenesis Compared With Micro...

Hip Arthroscopy

Actively Recruiting

1 location

Evaluation of the Effectiveness and Safety of Autologous Cos...

Articular Cartilage Defect

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here